BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36018546)

  • 1. Identification and validation of a poor clinical outcome subtype of primary prostate cancer with Midkine abundance.
    Zhou Q; Yang C; Mou Z; Wu S; Dai X; Chen X; Ou Y; Zhang L; Sha J; Jiang H
    Cancer Sci; 2022 Nov; 113(11):3698-3709. PubMed ID: 36018546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral CXCL13
    Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral TIGIT
    Liu Z; Zhou Q; Wang Z; Zhang H; Zeng H; Huang Q; Chen Y; Jiang W; Lin Z; Qu Y; Xiong Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang J; Chang Y; Zhang W
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of tumour-infiltrating CD103
    Zhou Q; Ou Y; Dai X; Chen X; Wu S; Chen W; Hu M; Yang C; Zhang L; Jiang H
    Br J Cancer; 2023 Apr; 128(8):1466-1477. PubMed ID: 36759726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state.
    Cerezo-Wallis D; Contreras-Alcalde M; Troulé K; Catena X; Mucientes C; Calvo TG; Cañón E; Tejedo C; Pennacchi PC; Hogan S; Kölblinger P; Tejero H; Chen AX; Ibarz N; Graña-Castro O; Martinez L; Muñoz J; Ortiz-Romero P; Rodriguez-Peralto JL; Gómez-López G; Al-Shahrour F; Rabadán R; Levesque MP; Olmeda D; Soengas MS
    Nat Med; 2020 Dec; 26(12):1865-1877. PubMed ID: 33077955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of novel inflammatory response-related gene signature to predict prostate cancer recurrence and response to immune checkpoint therapy.
    Luo Y; Liu X; Lin J; Zhong W; Chen Q
    Math Biosci Eng; 2022 Aug; 19(11):11345-11366. PubMed ID: 36124593
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Fan Y; Ge Y; Niu K; Li Y; Qi LW; Zhu H; Ma G
    Front Immunol; 2024; 15():1364329. PubMed ID: 38698844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells.
    Wang S; Huang M; Chen M; Sun Z; Jiao Y; Ye G; Pan J; Ye W; Zhao J; Zhang D
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses.
    Zeng H; Liu Z; Wang Z; Zhou Q; Qi Y; Chen Y; Chen L; Zhang P; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
    Int J Cancer; 2020 Jan; 146(2):542-552. PubMed ID: 31584197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Expression and CD8
    Petitprez F; Fossati N; Vano Y; Freschi M; Becht E; Lucianò R; Calderaro J; Guédet T; Lacroix L; Rancoita PMV; Montorsi F; Fridman WH; Sautès-Fridman C; Briganti A; Doglioni C; Bellone M
    Eur Urol Focus; 2019 Mar; 5(2):192-196. PubMed ID: 28753812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
    Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
    Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Midkine Suppresses Prostate Cancer CD133
    Erdogan S; Doganlar ZB; Doganlar O; Turkekul K; Serttas R
    Am J Med Sci; 2017 Sep; 354(3):299-309. PubMed ID: 28918838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer.
    Shao N; Tang H; Mi Y; Zhu Y; Wan F; Ye D
    Oncoimmunology; 2020 Jun; 9(1):1762473. PubMed ID: 32923125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WHSC1/NSD2 regulates immune infiltration in prostate cancer.
    Want MY; Tsuji T; Singh PK; Thorne JL; Matsuzaki J; Karasik E; Gillard B; Cortes Gomez E; Koya RC; Lugade A; Odunsi K; Battaglia S
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin
    Zhou Q; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Liu L; Zhu Y; Xu L; Dai B; Guo J; Xia Y; Wang Y; Xu J
    Oncoimmunology; 2020 Apr; 9(1):1747333. PubMed ID: 33457092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer.
    Nordin A; Wang W; Welén K; Damber JE
    Prostate; 2013 May; 73(6):657-67. PubMed ID: 23129424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma.
    Zhu WW; Guo JJ; Guo L; Jia HL; Zhu M; Zhang JB; Loffredo CA; Forgues M; Huang H; Xing XJ; Ren N; Dong QZ; Zhou HJ; Ren ZG; Zhao NQ; Wang XW; Tang ZY; Qin LX; Ye QH
    Clin Cancer Res; 2013 Jul; 19(14):3944-54. PubMed ID: 23719264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer.
    Zhang Y; Zuo C; Liu L; Hu Y; Yang B; Qiu S; Li Y; Cao D; Ju Z; Ge J; Wang Q; Wang T; Bai L; Yang Y; Li G; Shao Z; Gao Y; Li Y; Bian R; Miao H; Li L; Li X; Jiang C; Yan S; Wang Z; Wang Z; Cui X; Huang W; Xiang D; Wang C; Li Q; Wu X; Gong W; Liu Y; Shao R; Liu F; Li M; Chen L; Liu Y
    J Hepatol; 2021 Nov; 75(5):1128-1141. PubMed ID: 34171432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors.
    Maldonado AR; Klanke C; Jegga AG; Aronow BJ; Mahller YY; Cripe TP; Crombleholme TM
    J Gene Med; 2010 Jul; 12(7):613-23. PubMed ID: 20603890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The signal peptide of the tumor-shared antigen midkine hosts CD4+ T cell epitopes.
    Kerzerho J; Schneider A; Favry E; Castelli FA; Maillère B
    J Biol Chem; 2013 May; 288(19):13370-7. PubMed ID: 23553629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.